ValuEngine upgraded shares of Genmab As (OTCMKTS:GNMSF) from a sell rating to a hold rating in a research report report published on Wednesday morning.
Separately, Zacks Investment Research lowered Genmab As from a hold rating to a sell rating in a research report on Tuesday, January 9th.
GNMSF opened at $199.95 on Wednesday. Genmab As has a 52-week low of $163.00 and a 52-week high of $239.75. The company has a market cap of $12,815.56, a PE ratio of 69.91 and a beta of 0.55.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/genmab-as-gnmsf-upgraded-to-hold-by-valuengine.html.
Genmab As Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.